Home

Team

Investment Approach

For Entrepreneurs

Portfolio Companies

News & Events

Archive

News & Events

Page 16 17

19 20

Nuon Therapeutics Announces Results of Studies Confirming the Uric Acid Lowering Activity of Tranilast - SAN MATEO, Calif., June 22, 2010

22 / 06 / 2010

WOMEN�??S HEALTH COMPANY VIVEVE SPONSORS AWARD WINNING ABSTRACT AT ACOG

16 / 06 / 2010

NUON THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE 2A STUDY IN HYPERURICEMIA - Success allows initiation of phase 2b study in patients with gout

16 / 06 / 2010

Sunshine Heart - First Minimally Invasive C-Pulse Procedure

15 / 06 / 2010

ASX Announcement First Minimally Invasive C-Pulse Procedure Performed at University of Louisville Sydney, Australia

15 / 06 / 2010

CHEMGENEX ANNOUNCES POSITIVE SAFTEY DATA ON OMAPRO�?� PRESENTED AT ASCO

08 / 06 / 2010

Opal Therapeutics Inc and Massachusetts General Hospital enter Joint Development Collaboration and Initiate HIV Immunotherapy Clinical Studies - Therapeutic Vaccine Trials to Start in London, UK

07 / 06 / 2010

Xenome names Michael Aldridge as Executive Director Brisbane, Australia

25 / 05 / 2010

CoDa Therapeutics Achieves Positive Phase 2 Efficacy of NEXAGON® in Chronic Venous Leg Ulcers

25 / 05 / 2010

ASX Announcement - Third implant at University of Alabama Birmingham Medical Centre

24 / 05 / 2010

ASX Announcement First implant at Pennsylvania State University Sydney, 5 May 2010

05 / 05 / 2010

CHEMGENEX TO HOST INVESTOR BRIEFING MELBOURNE, Australia, and MENLO PARK, California U.S.A. (4 May 2010)

04 / 05 / 2010

CHEMGENEX RECEIVES A COMPLETE RESPONSE LETTER FROM THE FDA FOR OMAPROTM MELBOURNE, Australia, and MENLO PARK, California U.S.A. (12th April 2010)

12 / 04 / 2010

Hatchtech reveals head lice massacre

25 / 03 / 2010

Xenome Licenses Peptides from xdiscoverTM Library to MedImmune Brisbane, Australia - 23 March 2010

23 / 03 / 2010

US Food and Drug Administration's Oncologic Drug Advisory Committee Recommends Chemgenex Validate a Diagnostic Prior to Approval of OMAPRO�?� in Chronic Myeloid Leukemia Patients with T315I Mutation

23 / 03 / 2010

Issuance of Xen2174 Patent in Japan- Brisbane, Australia. 04 March 2010

04 / 03 / 2010

U.S. Food and Drug Administration (FDA) Sets 22 March for Oncologic Drugs Advisory Committee (ODAC) Meeting to Review OMAPRO�?� MELBOURNE, Australia, and MENLO PARK, California USA (2 March 2010)

02 / 03 / 2010

Sunshine Heart - First implant at University of Alabama Medical Centre

22 / 12 / 2009

ChemGenex, Hospira, Announce Agreement to License, Develop and Commercialize Leukemia Drug in Europe

18 / 12 / 2009

ChemGenex�??s Omapro�?� Featured During ASH Oral Session

09 / 12 / 2009

Pivotal Data on ChemGenex�??s Omapro�?� Highlighted at ASH Press Conference

07 / 12 / 2009

ChemGenex to Present Positive Data for Omapro�?� from Multiple Clinical Trials at ASH

01 / 12 / 2009

Chairman�??s Address for ChemGenex Pharmaceuticals Limited Annual General Meeting

30 / 11 / 2009

ChemGenex�??s Marketing Authorization Application for Omacetaxine Mepesuccinate Validated by the European Medicines Agency

27 / 11 / 2009

Displaying records 426-450 of 705